

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Aguilar Laura K.</u>  (Last) (First) (Middle) C/O CANDEL THERAPEUTICS, INC. 117 KENDRICK ST., SUITE 450  (Street) NEEDHAM MA 02494  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 07/26/2021	3. Issuer Name and Ticker or Trading Symbol <u>Candel Therapeutics, Inc. [ CADL ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) _____ Chief Medical Officer	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	874,943	D	
Common Stock	2,013,100	I	By Laura K. Aguilar 2020 Irrevocable Trust <sup>(1)</sup>

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (Right to Buy)	(2)	08/17/2028	Common Stock	17,901	1.46	D	
Stock Option (Right to Buy)	(3)	11/12/2028	Common Stock	76,717	1.46	D	
Series B Preferred Stock	(4)	(4)	Common Stock	56,096 <sup>(5)</sup>	(4)	D	

**Explanation of Responses:**

- Shares held by the Laura K. Aguilar 2020 Irrevocable Trust . The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein, if any.
- 25% of this option vested and became exercisable on January 1, 2019, with the remainder vesting in three substantially equal annual installments thereafter.
- This option shall vest and become exercisable in four substantially equal annual installments, with the first installment vesting on November 13, 2018.
- The Series B Preferred Stock has no expiration date.
- Includes 32,399 shares held jointly with spouse.

**Remarks:**

/s/ Laura K. Aguilar

07/26/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.